Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LEXX with free AI briefings, catalyst countdowns, and dilution alerts.

LEXX · Lexaria Bioscience Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.6M Cash on Hand
5.8mo Cash Runway
Follow LEXX by email Get an email when LEXX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LEXX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Arm 1 - DehydraTECH-CBD alone Type2diabetes Phase 1 · NCT06648031 Completed
Arm 2 - DehydraTECH-semaglutide alone Type2diabetes Phase 1 · NCT06648031 Completed
Arm 3 - DehydraTECH-CBD in combination with… Type2diabetes Phase 1 · NCT06648031 Completed
Arm 4 - Rybelsus medication (semaglutide) alone Type2diabetes Phase 1 · NCT06648031 Completed
Arm 5- Tirzepatide Type2diabetes Phase 1 · NCT06648031 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LEXX holds $3.6M in cash and short-term investments (as of May 31, 2026) and burns about $1.9M/quarter from operations, an estimated runway of 5.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LEXX files for a raise →

👥 Who Owns LEXX

Insiders 3% Institutions (19 holders) 4.4% Public and other holders 92.6%
HolderTypeShares% of sharesAs of
Christopher Bunka
Director · +577,336 options
Insider 555,455 2.24% 2026-03-17
Armistice Capital, LLC Institution (13G, 5%+) 172,084 0.69% 2026-09-30
Richard Christopher
Chief Executive Officer, Director · +550,000 options
Insider 65,000 0.26% 2025-07-29
John Martin Docherty
President & CSO, Director · +664,336 options
Insider 59,451 0.24% 2025-07-29
William Edward McKechnie
Director · +231,800 options
Insider 18,191 0.07% 2025-07-29
Baljinder Bhullar
Director · +11,000 options
Insider 13,000 0.05% 2025-05-15
Nicholas W Baxter
Director · +231,800 options
Insider 11,000 0.04% 2025-05-15
Albert L Jr Reese
Director · +126,800 options
Insider 10,917 0.04% 2025-05-15
Catherine C. Turkel
Director · +60,400 options
Insider 3,100 0.01% 2024-08-12
Vanessa Carle
Secretary · +225,000 options
Insider 750 0.00% 2025-07-29

Share count 24,787,446 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LEXX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LEXX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.